CVS Health Corporation (CVS) has agreed to acquire the entire outstanding shares of Aetna for a total consideration of $77bn.

The shareholders of the target company will be paid $145 a share in cash and issued 0.8378 CVS shares for each Aetna share held. The target company shareholders will hold 22% of the merged company, while the remaining will be held by the acquirer company shareholders.

The transaction will integrate the expertise of CVS and Aetna to redefine consumer healthcare experience and build a healthcare platform for individuals.

“NeuroSearch has announced its intention to be sold to a potential buyer in 2018.”

NeuroSearch has announced its intention to be sold to a potential buyer in 2018.

Based in Denmark, NeuroSearch is a biotechnology company involved in developing pharmaceuticals for the treatment of diseases and disorders.

The firm plans for voluntary liquidation in case it does not secure a satisfactory bid.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The net proceeds of liquidation are intended to be distributed to the shareholders.